The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -109,524 |
| Depreciation and amortization | 969 |
| Stock-based compensation expense | 11,415 |
| Realized gain from sale of marketable securities | 1,227 |
| Non cash operating lease expense | 572 |
| Amortization of (discount) premium on marketable securities | -637 |
| Foreign currency exchange loss (gain) | 555 |
| Non-cash interest expense and amortization of issuance costs | 11,796 |
| Fair value adjustment to derivative liability | -3,426 |
| Impairment of right of use assets | 1,190 |
| Research and development tax credit receivable | 4,809 |
| Accounts receivable, net | 2,593 |
| Inventory | 3,428 |
| Prepaid expenses and other assets | -10,778 |
| Accounts payable | 4,191 |
| Accrued expenses and other liabilities | -3,828 |
| Deferred revenue | 643 |
| Net cash used in operating activities | -81,621 |
| Purchases of marketable securities | 84,784 |
| Sales and maturities of marketable securities | 105,364 |
| Acquisition of property and equipment | 1,707 |
| Capitalized website development costs | 189 |
| Net cash provided by (used in) investing activities | 18,684 |
| Proceeds from sale of convertible notes, net of offering costs | 139,049 |
| Proceeds from the royalty agreement, net of issuance costs | 21,670 |
| Issuance of common stock from equity incentive plans | 1,228 |
| Issuance of common stock from employee stock purchase plan | 694 |
| Net cash provided by financing activities | 162,641 |
| Effect of exchange rate changes | -1,831 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 97,873 |
| Cash, cash equivalents and restricted cash at beginning of the period | 132,272 |
| Cash, cash equivalents and restricted cash at end of the period | 230,145 |
| Less restricted cash in other assets | 803 |
| Cash and cash equivalents | 229,342 |
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)